Home Newsfeeds Citigroup Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

Citigroup Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

Citigroup analyst Neena Bitritto-Garg maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $7 to $5.

byBenzinga Newsdesk

November 16, 2022

1 minute read

Citigroup analyst Neena Bitritto-Garg maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $7 to $5.

British Pound Drops To All-Time Lows: ‘Existential Crisis Is Looming’

By Wayne Duggan

September 26, 11:10 AM

The iShares MSCI United Kingdom ETF (NYSE: EWU) traded lower by another 0.8% on Monday and is now down 7.5% overall in the last five days as investors continue to react to

EWU

What’s Going On With Electric Vertical Take-Off And Landing Jet Company Lilium Wednesday?

By Anusuya Lahiri

May 29, 8:57 AM

Lilium NV's stock rises as Volare Aviation acquires 4 Lilium Jets and secures production slots. Lilium expands partnership with Luxaviation Group.

GWX

Apollomics Announces Two New Cohorts In Global Phase 2 SPARTA Study Of Vebreltinib In Non-Small Cell Lung Cancer And Other Solid Tumors With MET Dysregulation

By Benzinga Newsdesk

October 31, 8:41 AM

The first new cohort, labeled C-2, is evaluating the addition of vebreltinib to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, such as osimertinib, for patients with EGFR-mutated NSCLC progressing on

APLM

US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April Ahead

By Shanthi Rexaline

March 27, 7:13 AM

Bargain hunters may flock to the market on Wednesday following three consecutive sessions of losses.

BTC

Citigroup Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

Related Posts

British Pound Drops To All-Time Lows: ‘Existential Crisis Is Looming’

What’s Going On With Electric Vertical Take-Off And Landing Jet Company Lilium Wednesday?

Apollomics Announces Two New Cohorts In Global Phase 2 SPARTA Study Of Vebreltinib In Non-Small Cell Lung Cancer And Other Solid Tumors With MET Dysregulation

US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April Ahead